Recombinant Anti-CD133 x Anti-EGFR Bispecific Antibody (Fv-IgG) is an appended IgG format, which has 2+2 antigen-binding valency. This dual variable domain IgG is generated by appending variable domains of an anti-CD133 IgG with similar domains from an anti-EGFR antibody via short peptide linkers, or vice versa. This BsAb can target brain tumor stem cells. It is designed for the research of Head and neck cancer; Colorectal cancer (CRC); Glioblastoma multiforme (GBM); Squamous cancer; Glioblastoma; Medulloblastoma; Non-small cell lung cancer (NSCLC); Renal cell cancer (RCC); Solid tumors therapy.
There are currently no customer reviews or questions for Recombinant Anti-CD133 x Anti-EGFR Bispecific Antibody (Fv-IgG) (BSDG-031). Click the button below to contact us or submit your feedback about this product.
Welcome! For price inquiries, we will get back to you as soon as possible.
INQUIRYSERVICES
PRODUCTS
PLATFORMS